Clinical impact and cost of laboratory monitoring need review even in resource-rich setting

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 3, 2011, Pages

  Sayana, Shilpa ^a   Javanbakht, Marjan ^b   Weinstein, Michael ^a   Khanlou, Homayoon ^a  

^a AIDS HEALTHCARE FOUNDATION   (United States)

^b University of Los Angeles   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LABORATORY MONITORING; LABORATORY TEST; LETTER; MAJOR CLINICAL STUDY; MEDICAL RECORD; PATIENT MONITORING; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED STATES;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CLINICAL LABORATORY TECHNIQUES; COHORT STUDIES; DRUG MONITORING; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79951777824     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31820472e8     Document Type: Letter

References (10)

1. Koenig SP, Schackman BR, Riviere C, et al. Clinical impact and cost of monitoring for asymptomatic laboratory abnormalities among patients receiving antiretroviral therapy in a resource-poor setting. Clin Infect Dis. 2010;51:600-608.
2. DART Trial Team. The Development of Antiretroviral Therapy in Africa (DART) Trial. Comparison of routine vs clinically driven laboratory monitoring in HIV-infected African adults over 5 years on ART: final resutls of the DART trial. Presented at 5th IAS Conference on HIV pathogenesis, Treatment, and Prevention; July 19-22, 2009; Cape Town, South Africa.
3. Kaiser Daily HIV/AIDS Report. Available at: http://www.kaisernetwork.org/ daily-reports/ rep-index.cfm?DR-ID=12268. Accessed December 11, 2009.
4. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55:1-17; quiz CE1-CE4.
5. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007;146:87-95. (Pubitemid 351640011)
6. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293-299.
7. Harrison KM, Song R, Zhang X. Life expectancy after HIV diagnosis based on National HIV Surveillance data from 25 States, United States. J Acquir Immune Defic Syndr. 2010;53:124-130.
8. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents. Department of Health and Human Services. December 1, 2009; 1-61. Available at: http://www.aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL.pdf. Accessed on December 11, 2009.
9. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129. (Pubitemid 34786200)
10. VogelM, Rockstroh JK. Liver disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation. Curr Opin HIVAIDS. 2009;4:171-175.